E

Everest Medicines Ltd
HKEX:1952

Watchlist Manager
Everest Medicines Ltd
HKEX:1952
Watchlist
Price: 37.7 HKD -2.71% Market Closed
Market Cap: 12.3B HKD
Have any thoughts about
Everest Medicines Ltd?
Write Note

Intrinsic Value

The intrinsic value of one Everest Medicines Ltd stock under the Base Case scenario is 30.72 HKD. Compared to the current market price of 37.7 HKD, Everest Medicines Ltd is Overvalued by 19%.

The Intrinsic Value is calculated as the average of DCF and Relative values:

Intrinsic Value
30.72 HKD
Overvaluation 19%
Intrinsic Value
Price
E
Base Case Scenario

Valuation Backtest
Everest Medicines Ltd

Backtest Intrinsic Value
Dive into the past to invest in the future

Uncover deeper insights with the Valuation Backtest. Learn how current stock valuations stack up against historical averages to gauge true investment potential.

Start backtest now and learn if your stock is truly undervalued or overvalued!

Run Backtest
Backtest Conclusion
Very Attractive
Current Valuation
+45%
Avg Valuation
-12%
Worst Valuation
-49%
Best Valuation
+45%

Stock is trading at its lowest valuation over the past 5 years.

Backtest Example
Register to View Results
Register to View Results

To access the results of this valuation backtest, please register an account with us. Registration is quick and gives you instant access to insights on 3 stocks per week for free.

Backtest Unavailable

The backtest for Everest Medicines Ltd cannot be conducted due to limitations such as insufficient data or other constraints. Please select a different stock or adjust your settings.

Backtest In Progress...
Backtest In Progress...
How do you feel about Everest Medicines Ltd?
Bearish
Neutral
Bullish

Fundamental Analysis

Company Quality
No Indicators Selected
Select Indicators

Select up to 3 indicators:

Insider Trading
0-3
Months
0-6
Months
0-12
Months
0-36
Months
No Periods Selected
Select Periods

Select up to 2 periods:

Investment Journal
AI Assistant
AI Assistant
Ask me anything about Everest Medicines Ltd

Provide an overview of the primary business activities
of Everest Medicines Ltd.

What unique competitive advantages
does Everest Medicines Ltd hold over its rivals?

What risks and challenges
does Everest Medicines Ltd face in the near future?

Summarize the latest earnings call
of Everest Medicines Ltd.

Is it considered overvalued or undervalued
based on the latest financial data?

Show all valuation multiples
for Everest Medicines Ltd.

Provide P/S
for Everest Medicines Ltd.

Provide P/E
for Everest Medicines Ltd.

Provide P/OCF
for Everest Medicines Ltd.

Provide P/FCFE
for Everest Medicines Ltd.

Provide P/B
for Everest Medicines Ltd.

Provide EV/S
for Everest Medicines Ltd.

Provide EV/GP
for Everest Medicines Ltd.

Provide EV/EBITDA
for Everest Medicines Ltd.

Provide EV/EBIT
for Everest Medicines Ltd.

Provide EV/OCF
for Everest Medicines Ltd.

Provide EV/FCFF
for Everest Medicines Ltd.

Provide EV/IC
for Everest Medicines Ltd.

Show me price targets
for Everest Medicines Ltd made by professional analysts.

What are the Revenue projections
for Everest Medicines Ltd?

How accurate were the past Revenue estimates
for Everest Medicines Ltd?

What are the Net Income projections
for Everest Medicines Ltd?

How accurate were the past Net Income estimates
for Everest Medicines Ltd?

What are the EPS projections
for Everest Medicines Ltd?

How accurate were the past EPS estimates
for Everest Medicines Ltd?

What are the EBIT projections
for Everest Medicines Ltd?

How accurate were the past EBIT estimates
for Everest Medicines Ltd?

Compare the revenue forecasts
for Everest Medicines Ltd with those of its competitors based on recent analyst estimates.

Compare the intrinsic valuations
of Everest Medicines Ltd and its key competitors using the latest financial data.

Compare historical revenue growth rates
of Everest Medicines Ltd against its competitors.

Analyze the profit margins
(gross, operating, and net) of Everest Medicines Ltd compared to its peers.

Compare the P/E ratios
of Everest Medicines Ltd against its peers.

Discuss the investment returns and shareholder value creation
comparing Everest Medicines Ltd with its peers.

Analyze the financial leverage
of Everest Medicines Ltd compared to its main competitors.

Show all profitability ratios
for Everest Medicines Ltd.

Provide ROE
for Everest Medicines Ltd.

Provide ROA
for Everest Medicines Ltd.

Provide ROIC
for Everest Medicines Ltd.

Provide ROCE
for Everest Medicines Ltd.

Provide Gross Margin
for Everest Medicines Ltd.

Provide Operating Margin
for Everest Medicines Ltd.

Provide Net Margin
for Everest Medicines Ltd.

Provide FCF Margin
for Everest Medicines Ltd.

Show all solvency ratios
for Everest Medicines Ltd.

Provide D/E Ratio
for Everest Medicines Ltd.

Provide D/A Ratio
for Everest Medicines Ltd.

Provide Interest Coverage Ratio
for Everest Medicines Ltd.

Provide Altman Z-Score Ratio
for Everest Medicines Ltd.

Provide Quick Ratio
for Everest Medicines Ltd.

Provide Current Ratio
for Everest Medicines Ltd.

Provide Cash Ratio
for Everest Medicines Ltd.

What is the historical Revenue growth
over the last 5 years for Everest Medicines Ltd?

What is the historical Net Income growth
over the last 5 years for Everest Medicines Ltd?

What is the current Free Cash Flow
of Everest Medicines Ltd?

Discuss the annual earnings per share (EPS)
trend over the past five years for Everest Medicines Ltd.

Financials
Annual
Quarterly
TTM
Annual
Quarterly
TTM

Balance Sheet Decomposition
Everest Medicines Ltd

Current Assets 2.3B
Cash & Short-Term Investments 1.9B
Receivables 293.6m
Other Current Assets 35.2m
Non-Current Assets 2.9B
Long-Term Investments 44.9m
PP&E 679.4m
Intangibles 2.2B
Other Non-Current Assets 8.1m
Current Liabilities 481.5m
Accounts Payable 70.3m
Accrued Liabilities 51.7m
Other Current Liabilities 359.6m
Non-Current Liabilities 284.2m
Long-Term Debt 278.3m
Other Non-Current Liabilities 6m
Efficiency

Earnings Waterfall
Everest Medicines Ltd

Revenue
418.6m CNY
Cost of Revenue
-101.5m CNY
Gross Profit
317m CNY
Operating Expenses
-1.1B CNY
Operating Income
-750.8m CNY
Other Expenses
-302.5m CNY
Net Income
-1.1B CNY

Free Cash Flow Analysis
Everest Medicines Ltd

Last Value
3-Years Average
FCF Margin
Conversion Rate
Earnings Calls

In the first half of 2024, Everest Medicines reported a 158% increase in revenue, reaching RMB 301.5 million, driven by strong sales from XERAVA and the launch of Nefecon in May. The company's cash gross margin was 83%, maintaining operational efficiency while reducing operating expenses as a percentage of revenue by 29%. Everest achieved profitability at a commercial level for the first time and expects to meet their full-year revenue guidance of RMB 700 million. With RMB 1.93 billion in cash, they are well-positioned to continue their growth strategy, including advancing their mRNA therapeutic vaccine program.

What is Earnings Call?
Fundamental Scores

Profitability Score
Profitability Due Diligence

Everest Medicines Ltd's profitability score is 33/100. The higher the profitability score, the more profitable the company is.

Exceptional Revenue Growth Forecast
Positive Gross Profit
Exceptional 1-Year Revenue Growth
ROE is Increasing
33/100
Profitability
Score

Everest Medicines Ltd's profitability score is 33/100. The higher the profitability score, the more profitable the company is.

Solvency Score
Solvency Due Diligence

Everest Medicines Ltd's solvency score is 75/100. The higher the solvency score, the more solvent the company is.

High Altman Z-Score
Short-Term Solvency
Long-Term Solvency
Negative Net Debt
75/100
Solvency
Score

Everest Medicines Ltd's solvency score is 75/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

Price Targets Summary
Everest Medicines Ltd

Wall Street analysts forecast Everest Medicines Ltd stock price to drop over the next 12 months.

According to Wall Street analysts, the average 1-year price target for Everest Medicines Ltd is 29.82 HKD with a low forecast of 24.75 HKD and a high forecast of 46.2 HKD.

Lowest
Price Target
24.75 HKD
34% Downside
Average
Price Target
29.82 HKD
21% Downside
Highest
Price Target
46.2 HKD
23% Upside
View Analyst Estimates
View Analyst Estimates
Want to learn more about Wall St estimates for Everest Medicines Ltd?

Click here to dive deeper.

Dividends

Everest Medicines Ltd
does not pay dividends
Shareholder Yield

Current shareholder yield for Everest Medicines Ltd is .

Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?

Shareholder Yield
Dividend Yield
No dividends
Buyback Yield
Lowest
Average
Highest
Debt Paydown Yield
Lowest
Average
Highest

Profile

Everest Medicines Ltd

Country

China

Industry

Biotechnology

Market Cap

12.1B HKD

Dividend Yield

0%

Description

Everest Medicines Ltd. operates as a biopharmaceutical company which focuses on licensing, clinical development and commercialization of globally therapies to address critical unmet medical needs in Greater China and other emerging Asia Pacific markets. The company is headquartered in Shanghai, Shanghai and currently employs 405 full-time employees. The company went IPO on 2020-10-09. The firm is focusing on the research and development of innovative drug candidate. The firm built a portfolio of promising clinical-stage drug candidates across oncology, immunology, cardio-renal disease and infectious disease. The firm mainly provides its products and services in Greater China and other emerging Asia Pacific markets.

Contact

SHANGHAI
Shanghai
Plaza 66, Tower 1, Units 6601-6606, 1266 West Nanjing Road
www.everestmedicines.com

IPO

2020-10-09

Employees

405

Officers

Executive Chairman
Mr. Fu Wei
CEO & Executive Director
Mr. Yongqing Luo
CFO, President & Executive Director
Mr. Ian Ying Woo
Chief Business Officer
Dr. Jason M. Brown Ph.D.
Chief Scientific Officer
Dr. Wei Yang Ph.D.
Chief Legal & Compliance Officer
Mr. Steve Xu
Show More
Chief Product Officer
Mr. Rico Liang
Chief Medical Officer
Ms. Sandra Zeng
Joint Company Secretary
Ms. Yee Wa Lau
Joint Company Secretary & VP of Corporate Affairs
Ms. Leah Liu
Show Less

See Also

Discover More
What is the Intrinsic Value of one Everest Medicines Ltd stock?

The intrinsic value of one Everest Medicines Ltd stock under the Base Case scenario is 30.72 HKD.

Is Everest Medicines Ltd stock undervalued or overvalued?

Compared to the current market price of 37.7 HKD, Everest Medicines Ltd is Overvalued by 19%.

Back to Top